Zdrowie i gospodarka · 14.08.2023
Request for Letters of Interest (LOI) for NCI-ComboMATCH Laboratories
The National Cancer Institute has developed a successor precision medicine trial, NCI-ComboMATCH, to overcome drug resistance to single-agent therapy by developing genomically-directed targeted agent combinations.